Constitutive coupling of a naturally occurring human alpha1a-adrenergic receptor genetic variant to EGFR transactivation pathway

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 49, 2011, Pages 19796-19801

  Oganesian, Anush ^a   Yarov Yarovoy, Vladimir ^c   Parks, William C ^a   Schwinn, Debra A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; ALPHA 1A ADRENERGIC RECEPTOR; BETA ARRESTIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; ENZYME ACTIVATION; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ADAM PROTEINS; AMINO ACID SUBSTITUTION; ANIMALS; ARRESTINS; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; DIPEPTIDES; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; MATRIX METALLOPROTEINASE 7; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; MUTATION; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ADRENERGIC, ALPHA-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TYRPHOSTINS;

EID: 83755183109     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1116271108     Document Type: Article

References (38)

1. 1)-adrenergic receptors by vessel bed and age. Circulation 100:2336-2343.
2. Autelitano DJ, Woodcock EA (1998) Selective activation of alpha1A-adrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of alpha1-adrenergic receptor subtype mRNAs. J Mol Cell Cardiol 30: 1515-1523. (Pubitemid 28418642)
3. Rokosh DG, Simpson PC (2002) Knockout of the alpha 1A/C-adrenergic receptor subtype: The alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA 99:9474-9479. (Pubitemid 34764638)
4. Zusman RM (2000) The role of alpha 1-blockers in combination therapy for hypertension. Int J Clin Pract 54:36-40.
5. Rockman HA, Koch WJ, Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212. (Pubitemid 34059526)
6. Noma T, et al. (2007) Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117:2445-2458.
7. Wang X, et al. (2009) Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 119:2480-2489.
8. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C (2004) Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 94:68-76. (Pubitemid 38064100)
9. Zhuang S, Kinsey GR, Rasbach K, Schnellmann RG (2008) Heparin-binding epidermal growth factor and Src family kinases in proliferation of renal epithelial cells. Am J Physiol Renal Physiol 294:F459-F468. (Pubitemid 351442216)
10. Prenzel N, et al. (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884-888.
11. Liggett SB (2010) Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. Heart Fail Clin 6:27-33.
12. Flordellis C, Manolis A, Scheinin M, Paris H (2004) Clinical and pharmacological significance of α2-adrenoceptor polymorphisms in cardiovascular diseases. Int J Cardiol 97:367-372. (Pubitemid 39550682)
13. Lei B, et al. (2005) Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function. Naunyn Schmiedebergs Arch Pharmacol 371:229-239. (Pubitemid 40768415)
14. Freitas SR, Pereira AC, Floriano MS, Mill JG, Krieger JE (2008) Association of alpha1aadrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population. BMC Cardiovasc Disord 8:40-47.
15. Gu D, et al. (2006) Association of alpha1A adrenergic receptor gene variants on chromosome 8p21 with human stage 2 hypertension. J Hypertens 24:1049-1056. (Pubitemid 43772312)
16. Nagareddy PR, MacLeod KM, McNeill JH (2010) GPCR agonist-induced transactivation of the EGFR upregulates MLC II expression and promotes hypertension in insulin-resistant rats. Cardiovasc Res 87:177-186.
17. Mifune M, et al. (2005) G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 280:26592-26599. (Pubitemid 41022257)
18. Gonzalez-Cabrera PJ, et al. (2004) Differential regulation of the cell cycle by alpha1- adrenergic receptor subtypes. Endocrinology 145:5157-5167. (Pubitemid 39551137)
19. Fuentes LQ, et al. (2008) Vasopressin up-regulates the expression of growth-related immediate-early genes via two distinct EGF receptor transactivation pathways. Cell Signal 20:1642-1650.
20. Morris DP, Price RR, Smith MP, Lei B, Schwinn DA (2004) Cellular trafficking of human alpha1a-adrenergic receptors is continuous and primarily agonist-independent. Mol Pharmacol 66:843-854. (Pubitemid 39319456)
21. Labasque M, et al. (2010) Constitutive activity of serotonin 2C receptors at G proteinindependent signaling: Modulation by RNA editing and antidepressants. Mol Pharmacol 78:818-826.
22. Sunnarborg SW, et al. (2002) Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 277: 12838-12845. (Pubitemid 34952648)
23. Goishi K, et al. (1995) Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: Conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 6:967-980.
24. Daub H, Weiss FU, Wallasch C, Ullrich A (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379:557-560. (Pubitemid 26049585)
25. Lefkowitz RJ, Shenoy SK (2005) Transduction of receptor signals by beta-arrestins. Science 308:512-517.
26. Shenoy SK, et al. (2006) Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 281:1261-1273.
27. Charest PG, Oligny-Longpré G, Bonin H, Azzi M, Bouvier M (2007) The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell Signal 19:32-41. (Pubitemid 44880240)
28. Wei H, et al. (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787. (Pubitemid 37140105)
29. DeFea KA, et al. (2000) The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97:11086-11091.
30. Kuo FT, Lu TL, Fu HW (2006) Opposing effects of β-arrestin1 and β-arrestin2 on activation and degradation of Src induced by protease-activated receptor 1. Cell Signal 18:1914-1923.
31. Stanasila L, Abuin L, Dey J, Cotecchia S (2008) Different internalization properties of the alpha1a- and alpha1b-adrenergic receptor subtypes: The potential role of receptor interaction with beta-arrestins and AP50. Mol Pharmacol 74:562-573.
32. Wu G, Krupnick JG, Benovic JL, Lanier SM (1997) Interaction of arrestins with intracellular domains of muscarinic and alpha2-adrenergic receptors. J Biol Chem 272: 17836-17842. (Pubitemid 27311226)
33. Chalothorn D, et al. (2002) Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol Pharmacol 61:1008-1016. (Pubitemid 34441765)
34. Pediani JD, et al. (2005) Beta-arrestin-dependent spontaneous alpha1a-adrenoceptor endocytosis causes intracellular transportation of alpha-blockers via recycling compartments. Mol Pharmacol 67:992-1004. (Pubitemid 40410401)
35. Intengan HD, Schiffrin EL (2000) Structure and mechanical properties of resistance arteries in hypertension: Role of adhesion molecules and extracellular matrix determinants. Hypertension 36:312-318.
36. Rostomily RC, et al. (1997) Pleomorphic xanthoastrocytoma: DNA flow cytometry and outcome analysis of 12 patients. Cancer 80:2141-2150. (Pubitemid 27506028)
37. Kim DE, Chivian D, Baker D (2004) Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 32(Web Server issue):W526-W531.
38. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P (2008) Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 19:563-571. (Pubitemid 351272145)